Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287911 · ClinicalTrials.gov registry record · Phase 1
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00287911 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 18 participants.
The verdict
NCT00287911, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as topotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Topotecan and cisplatin may make tumor cells more sensitive to radiation therapy. Giving topotecan and cisplatin together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of topotecan when given together with cisplatin and radiation therapy in treating patients with advanced cervical cancer.
Interventions
- DRUG cisplatin
- RADIATION radiation therapy
- RADIATION brachytherapy
- DRUG topotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-02 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287911
The ClinicalTrials.gov registry entry for NCT00287911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00287911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287911 about?
NCT00287911 is a clinical study titled "Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer". RATIONALE: Drugs used in chemotherapy, such as topotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Internal radiation uses radioactive material...
What is the current status of trial NCT00287911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2005-02. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00287911?
The interventions under investigation include: cisplatin (DRUG), radiation therapy (RADIATION), brachytherapy (RADIATION), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00287911?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.